Track Steminent Biotherapeutics's other current assets ($21M) with charts, peers, and YoY trends.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
Steminent Biotherapeutics posts a other current assets of $21M as of September 2026. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.
Other Current Assets is one piece of Steminent Biotherapeutics's financial statement story. At $21M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.
Context for 7729.TWO's other current assets usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Steminent Biotherapeutics's other metric pages and overview cover the third.
Judging Steminent Biotherapeutics against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in other current assets easier to interpret. Start with $21M here, then scan peer and history charts to see if the gap is persistent.